Below is our Corporate / M&A decisions update covering decisions in the second quarter of 2024. Decisions from the Delaware Court of Chancery ...
↘️ Applied Materials (AMAT): Shares fell 8% after the semiconductor-equipment company posted a weaker-than-expected sales ...
A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...
Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...
Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...
European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...